Study Examines Chemotherapy Options for Partially Platinum-Sensitive OC Patients

Study Examines Chemotherapy Options for Partially Platinum-Sensitive OC Patients
Platinum-based chemotherapy (PBC) should be not be delayed in favor of non-platinum-based chemotherapy (NPBC) in patients with partially platinum-sensitive ovarian cancer, a new study shows. The study, “Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study,” was published in the Journal of Clinical Oncology. Ovarian cancer tends to progress despite surgery and PBC, the latter being the first-line chemotherapy offered to patients. Upon progression, patients can be re-treated with PBC, but the effectiveness of treating again with PBC is increased if the period of time since initial PBC is longer. So, if recurrence comes within six months of the first PBC treatment (platinum resistant), patients are treated with NPBC; and, if patients progress after 12 months of the first PBC (platinum sensitive), they are treated with PBC. There is, however, uncertainty on what to do when a patient progresses between six and 12 months (partially platinum-sensitive). In 1999, it was hypothesized that NPBC could be a means of increasing the time since first PBC and enhancing the sensitivity to PBC re-treatment in partially platinum-sensitive patients. However, in 2006, a study conducted by the Multicenter Italian Trials in Ovarian Cancer (MITO) group suggested that NPBC after initial PBC treatment may not be the best choice. In 2008, researchers launched MITO-8 (
Subscribe or to access all post and page content.